MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
65.27
-1.81
-2.70%
After Hours: 65.66 +0.39 +0.60% 18:08 04/25 EDT
OPEN
67.47
PREV CLOSE
67.08
HIGH
67.90
LOW
65.09
VOLUME
15.16M
TURNOVER
0
52 WEEK HIGH
87.87
52 WEEK LOW
65.09
MARKET CAP
81.39B
P/E (TTM)
14.49
1D
5D
1M
3M
1Y
5Y
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 2h ago
Gilead Sciences Inc. Q1 Earnings Summary
NASDAQ · 3h ago
UPDATE 1-Gilead posts quarterly loss on acquisition charge, revenue rises 5%
Gilead Sciences posts quarterly loss on acquisition charge, revenue rises 5% on higher HIV, oncology and liver disease treatment sales. Company took $3.9 billion charge for recent acquisition of liver drug developer CymaBay Therapeutics. Shares of Gilead were up 3.3% in after hours trading.
Reuters · 3h ago
GILEAD EXPECTS COMPANY'S HIV SALES TO BE ROUGHLY FLAT IN 2025 - CONF. CALL
Reuters · 3h ago
GILEAD: MARKET VOLUMES IN FEBRUARY WERE TEMPORARILY DISRUPTED BY CYBER ATTACK ON CHANGE HEALTHCARE, VOLUMES READILY RECOVERED IN MARCH - CONF. CALL
Reuters · 3h ago
GILEAD EXEC SAYS IT IS UNLIKELY THAT COMPANY WILL BE ENGAGING IN ANY SIZABLE M&A TRANSACTIONS IN THE NEAR TERM - CONF. CALL
Reuters · 3h ago
Gilead’s quarterly loss is narrower than expected
MarketWatch · 4h ago
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
Gilead Sciences posts higher first-quarter sales, but swings to a steep loss due to charges related to recent acquisitions. The biopharmaceutical company reported a loss of $4.17 billion, or $3.34 a share. Total revenue rose about 5% to $6.67 billion, ahead of analyst expectations. Gilead now expects full-year earnings of between 10 cents and 50 cents.
Dow Jones · 4h ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Webull offers Gilead Sciences, Inc. stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.